Last reviewed · How we verify
OKN-007
At a glance
| Generic name | OKN-007 |
|---|---|
| Also known as | Anti-Cancer Agent, NXY-059, HPN-07 |
| Sponsor | Oblato, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma (PHASE1)
- Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (PHASE2)
- Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma (PHASE1)
- Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
- Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients (PHASE1)
- Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OKN-007 CI brief — competitive landscape report
- OKN-007 updates RSS · CI watch RSS
- Oblato, Inc. portfolio CI